Updated meta-analysis on neoadjuvant immunotherapy in early-stage NSCLC
Event-free survival improves across trials; overall survival data are still maturing.
[Demo] Neoadjuvant immunotherapy in resectable NSCLC: an updated meta-analysisDemo Oncology Reviews · 2026doi:10.5555/demo.nsclc.2026
Does neoadjuvant immunotherapy improve survival in early-stage NSCLC?Expert review in progress1 of 2
Rigor
Source-linked
A source is linked. No one has checked the interpretation yet. Reach (likes, shares) never changes this label.